Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Acceleration of cutaneous T-cell lymphoma following dupilumab administration
Kristen Russomanno, Cynthia Marie Carver DeKlotz
JAAD Case Reports (2020) Vol. 8, pp. 83-85
Open Access | Times Cited: 39

Showing 1-25 of 39 citing articles:

Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND)
Vivian Y. Shi, Tina Bhutani, Luz Fonacier, et al.
Journal of the American Academy of Dermatology (2022) Vol. 87, Iss. 2, pp. 351-358
Open Access | Times Cited: 67
Dupilumab-Associated Adverse Events During Treatment of Allergic Diseases
Anna Kychygina, Myriam Cassagne, M. Tauber, et al.
Clinical Reviews in Allergy & Immunology (2022) Vol. 62, Iss. 3, pp. 519-533
Closed Access | Times Cited: 47
Cutaneous T‐cell lymphoma following dupilumab use: a systematic review
Ariel Park, Lulu Wong, Annalise Lang, et al.
International Journal of Dermatology (2022) Vol. 62, Iss. 7, pp. 862-876
Open Access | Times Cited: 41
Unveiling the Role of the Cellular Tumor Microenvironment and the Therapeutic Targets it Provides in Cutaneous T-Cell Lymphoma
Nikolaos A. Chinas, Stella Kaliampou, Vasiliki Nikolaou
Current Oncology Reports (2025)
Open Access
Mogamulizumab efficacy is underscored by its associated rash that mimics cutaneous T-cell lymphoma: a retrospective single-centre case series
Nicholas A. Trum, Jasmine Zain, X. Martínez, et al.
British Journal of Dermatology (2021) Vol. 186, Iss. 1, pp. 153-166
Open Access | Times Cited: 32
Development of Cutaneous T-Cell Lymphoma Following Biologic Treatment: A Systematic Review
Lauren Schaefer, Nneka I. Comfere, Olayemi Sokumbi
American Journal of Clinical Dermatology (2023) Vol. 24, Iss. 2, pp. 153-164
Closed Access | Times Cited: 11
Dupilumab-associated mycosis fungoides: a cross-sectional study
Austin Hamp, Jamie L. Hanson, Robert A. Schwartz, et al.
Archives of Dermatological Research (2023) Vol. 315, Iss. 9, pp. 2561-2569
Open Access | Times Cited: 11
Cutaneous T‐cell lymphoma and dupilumab use: A retrospective matched cohort study of clinical characteristics and treatment outcomes
Robert Stuver, Stephen W. Dusza, Zachary D. Epstein‐Peterson, et al.
Journal of the European Academy of Dermatology and Venereology (2024)
Closed Access | Times Cited: 4
T cells in the skin: Lymphoma and inflammatory skin disease
Ben Roediger, Christoph Schlapbach
Journal of Allergy and Clinical Immunology (2022) Vol. 149, Iss. 4, pp. 1172-1184
Open Access | Times Cited: 17
Real-Life Barriers to Diagnosis of Early Mycosis Fungoides: An International Expert Panel Discussion
Emmilia Hodak, Larisa J. Geskin, Emmanuella Guenova, et al.
American Journal of Clinical Dermatology (2022) Vol. 24, Iss. 1, pp. 5-14
Open Access | Times Cited: 16
Eosinophilia and elevated IgE serum levels: a red flag: when your diagnosis is not a common atopic eczema or common allergy
Paulo Ricardo Criado, Hélio Amante Miot, Mayra Ianhez
Inflammation Research (2023) Vol. 72, Iss. 3, pp. 541-551
Closed Access | Times Cited: 10
An update on mechanisms of pruritus and their potential treatment in primary cutaneous T-cell lymphoma
Man Hu, Jörg Scheffel, Daniel Elieh Ali Komi, et al.
Clinical and Experimental Medicine (2023) Vol. 23, Iss. 8, pp. 4177-4197
Open Access | Times Cited: 9
The Microenvironment’s Role in Mycosis Fungoides and Sézary Syndrome: From Progression to Therapeutic Implications
Alessandro Pileri, Alba Guglielmo, Vieri Grandi, et al.
Cells (2021) Vol. 10, Iss. 10, pp. 2780-2780
Open Access | Times Cited: 23
Safety and Danger Considerations of Novel Treatments for Atopic Dermatitis in Context of Primary Cutaneous Lymphomas
Karol Kołkowski, Magdalena Trzeciak, Małgorzata Sokołowska‐Wojdyło
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 24, pp. 13388-13388
Open Access | Times Cited: 20
Dupilumab‐associated psoriasis and psoriasiform dermatitis in patients with atopic dermatitis
Fiore Casale, Cristina Nguyen, Allison S. Dobry, et al.
Australasian Journal of Dermatology (2022) Vol. 63, Iss. 3, pp. 394-397
Closed Access | Times Cited: 14
Discordant lymphomas of classic Hodgkin lymphoma and peripheral T-cell lymphoma following dupilumab treatment for atopic dermatitis
Kumi Nakazaki, Mina Yoshida, Yosuke Masamoto, et al.
International Journal of Hematology (2022) Vol. 116, Iss. 3, pp. 446-452
Closed Access | Times Cited: 11
What Is New in Cutaneous T Cell Lymphoma?
Sarah Morgenroth, A Roggo, Laura Pawlik, et al.
Current Oncology Reports (2023) Vol. 25, Iss. 11, pp. 1397-1408
Open Access | Times Cited: 6
Advancements in the treatment of mycosis fungoides and Sézary syndrome: monoclonal antibodies, immunotherapies, and Janus kinase inhibitors
Iman Quadri, John Reneau, Walter Hanel, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 6
Dupilumab as a therapy option for treatment refractory mogamulizumab-associated rash
Nicholas A. Trum, Jasmine Zain, Chelsea Abad, et al.
JAAD Case Reports (2021) Vol. 14, pp. 37-42
Open Access | Times Cited: 12
A rare case of aggressive cytotoxic T-cell lymphoma in a patient on dupilumab
Renat Ahatov, Allison Good, Michael Joo, et al.
JAAD Case Reports (2022) Vol. 24, pp. 112-114
Open Access | Times Cited: 8
Lethal anaplastic large-cell lymphoma occurring in a patient treated with dupilumab
A. Du‐Thanh, Valentin Gustave, O. Dereure
JAAD Case Reports (2021) Vol. 18, pp. 4-7
Open Access | Times Cited: 11
Histology‐based classifier to distinguish early mycosis fungoides from atopic dermatitis
Sophie Roenneberg, Stephan A. Braun, Natalie Garzorz‐Stark, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 37, Iss. 11, pp. 2284-2292
Open Access | Times Cited: 4
Increased Risk of Cutaneous T‐Cell Lymphoma Development after Dupilumab Use for Atopic Dermatitis
Jenna Mandel, Jaanvi Mehta, R Häfer, et al.
Dermatologic Therapy (2024) Vol. 2024, Iss. 1
Open Access | Times Cited: 1
Dupilumab-Associated Mycosis Fungoides with a CD8+ Immunophenotype
Ariel Park, Lulu Wong, Annalise Lang, et al.
Dermatopathology (2022) Vol. 9, Iss. 4, pp. 385-391
Open Access | Times Cited: 6
Did dupilumab unmask smoldering mycosis fungoides?
Michelle Toker, Pooja Srivastava, Bijal Amin, et al.
JAAD Case Reports (2023) Vol. 38, pp. 11-13
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top